Global Hemophilia B Market: Overview

Hemophilia B is a bleeding disorder characterized by a lack of blood clotting factor IX. Factor IX is an important coagulation factor that is necessary for blood clotting, and it helps control bleeding. The process of blood clot formation is known as coagulation cascade, which uses clotting factors or coagulation factors. The disorder is caused by inherited X-linked recessive trait, a defected gene located on the X chromosome.

Global Hemophilia B Market: Key Trends

The hemophilia B treatment market is anticipated to expand at a significant growth rate due to factors such as recent product launches, increase in the number of regulatory approvals, and rise in demand for recombinant coagulation factors concentrates for the treatment of hemophilia B. For instance, in February 2018, Novo Nordisk A/S launched Rebinyn in the U.S. for the treatment of Hemophilia B thereby expending its product portfolio for rare disease treatment. In March 2014, Bioverativ Therapeutics, Inc. received FDA approval for Alprolix , a recombinant factor IX indicated for the treatment of hemophilia B. This enabled the company to cater to the needs of patients affected by hemophilia B. The launch of this drug offered a competition advantage to the company, increasing its share in the market. Further, promising drugs in the pipeline and increase in research and development (R&D) expenditure on the treatment of rare hematological disease are anticipated to support the growth of the market during the forecast period.

Global Hemophilia B Market: Segmentation

The global hemophilia B market can be segmented based on product, distribution channel, and region. In terms of product, the market can be divided into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, and others. The recombinant coagulation factor concentrates segment is anticipated to expand at a rapid CAGR during the forecast period, due to a shift from the use of plasma-derived coagulation factor concentrates to recombinant factors and increase in the availability of recombinant factors for the treatment of hemophilia B. In terms of distribution channel, the market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold a key market share, owing to a rise in investments in the rare disease management sectors by hospitals in emerging countries such as China, Japan, and other countries in Asia Pacific.

Global Hemophilia B Market: Regional Analysis

Based on region, the global hemophilia B market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for a prominent market share during the forecast period. The market in the region is driven by an increase in the number of mergers & acquisitions, agreements & partnerships, and other strategic approaches by market players and FDA approvals for recombinant coagulation factor concentrates. In Europe, the hemophilia B market is expected to be driven the introduction of recombinant therapies, rapid adoption of recombinant DNA technologies, and increase in R&D activities by market players. In Germany and the U.K., recombinant plasma protein therapeutics have received significant importance due to an increase commercial players offering products for hemophilia B and a high number of hemophilia patients treated with recombinant products. The market in Asia Pacific is expected to expand at the rapid CAGR during the forecast period, driven by an increase in the number of awareness campaigns regarding rare hematological disorders, geographical expansion by market players, and increase in the demand or novel therapies for the treatment of hemophilia B. In China and Japan, regulatory authorities have recently approved various recombinant plasma protein concentrates that have helped increase their availability in these countries.

Global Hemophilia B Market: Competitive Landscape

 Key players operating in the global hemophilia B market are Grifols, S.A., CSL Limited, Shire, Novo Nordisk A/S, Bioverativ Therapeutics, Inc., an affiliate of Sanofi, Pfizer Inc., Kedrion S.p.A, F. Hoffmann-La Roche Ltd., Aptevo Therapeutics, and Baxter.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.